Early Tirzepatide Triumphs in Type 2 Diabetes Study; Long COVID Breakthrough: Autoantibodies Unveiled

Recent studies show Eli Lilly's tirzepatide, sold as Mounjaro, is highly effective for managing early-diagnosed type 2 diabetes patients. Findings also reveal long COVID may be driven by autoantibodies, suggesting potential treatment pathways. The studies stress the importance of reassessing blood donation policies due to associated risks.

Devdiscourse News Desk | (This Is An Excerpt Of The Health Rounds Newsletter | Updated: 29-05-2026 16:30 IST | Created: 29-05-2026 16:30 IST

Early Tirzepatide Triumphs in Type 2 Diabetes Study; Long COVID Breakthrough: Autoantibodies Unveiled — This image is AI-generated and does not depict any real-life event or location. It is a fictional representation created for illustrative purposes only.

Eli Lilly's GLP-1 drug tirzepatide, known as Mounjaro, shows promising results for those newly diagnosed with type 2 diabetes, outperforming standard care treatments, researchers found.

A groundbreaking study in Annals of Internal Medicine reveals that nearly 60% of patients achieved normal blood sugar levels using tirzepatide versus 24% on other drugs.

Additionally, two studies identified autoantibodies as a potential cause of long COVID symptoms. The findings could lead to targeted treatments and highlight the need for revised blood donation policies to protect recipients from potential risks.

(With inputs from agencies.)